These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 21541048)

  • 1. Expression and clinical role of protein of regenerating liver (PRL) phosphatases in ovarian carcinoma.
    Reich R; Hadar S; Davidson B
    Int J Mol Sci; 2011 Feb; 12(2):1133-45. PubMed ID: 21541048
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic significance of phosphatase of regenerating liver-3 expression in ovarian cancer.
    Ren T; Jiang B; Xing X; Dong B; Peng L; Meng L; Xu H; Shou C
    Pathol Oncol Res; 2009 Dec; 15(4):555-60. PubMed ID: 19247814
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression and prognostic impact of the protein tyrosine phosphatases PRL-1, PRL-2, and PRL-3 in breast cancer.
    Radke I; Götte M; Kersting C; Mattsson B; Kiesel L; Wülfing P
    Br J Cancer; 2006 Aug; 95(3):347-54. PubMed ID: 16832410
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PRL-3 suppresses c-Fos and integrin α2 expression in ovarian cancer cells.
    Liu H; Al-aidaroos AQ; Wang H; Guo K; Li J; Zhang HF; Zeng Q
    BMC Cancer; 2013 Feb; 13():80. PubMed ID: 23418787
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The PAC-1 dual specificity phosphatase predicts poor outcome in serous ovarian carcinoma.
    Givant-Horwitz V; Davidson B; Goderstad JM; Nesland JM; Tropé CG; Reich R
    Gynecol Oncol; 2004 May; 93(2):517-23. PubMed ID: 15099972
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overexpression of phosphatase of regenerating liver-3 in breast cancer: association with a poor clinical outcome.
    Wang L; Peng L; Dong B; Kong L; Meng L; Yan L; Xie Y; Shou C
    Ann Oncol; 2006 Oct; 17(10):1517-22. PubMed ID: 16873432
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PRL tyrosine phosphatases regulate rho family GTPases to promote invasion and motility.
    Fiordalisi JJ; Keller PJ; Cox AD
    Cancer Res; 2006 Mar; 66(6):3153-61. PubMed ID: 16540666
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High PRL-3 expression in human gastric cancer is a marker of metastasis and grades of malignancies: an in situ hybridization study.
    Miskad UA; Semba S; Kato H; Matsukawa Y; Kodama Y; Mizuuchi E; Maeda N; Yanagihara K; Yokozaki H
    Virchows Arch; 2007 Mar; 450(3):303-10. PubMed ID: 17235563
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of phosphatase of regenerating liver 1 and 3 mRNA in esophageal squamous cell carcinoma.
    Liu YQ; Li HX; Lou X; Lei JY
    Arch Pathol Lab Med; 2008 Aug; 132(8):1307-12. PubMed ID: 18684031
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ets-1 mRNA expression in effusions of serous ovarian carcinoma patients is a marker of poor outcome.
    Davidson B; Risberg B; Goldberg I; Nesland JM; Berner A; Tropé CG; Kristensen GB; Bryne M; Reich R
    Am J Surg Pathol; 2001 Dec; 25(12):1493-500. PubMed ID: 11717538
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular mechanisms of the PRL phosphatases.
    Rios P; Li X; Köhn M
    FEBS J; 2013 Jan; 280(2):505-24. PubMed ID: 22413991
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PRL-3, an emerging marker of carcinogenesis, is strongly associated with poor prognosis.
    Guzińska-Ustymowicz K; Pryczynicz A
    Anticancer Agents Med Chem; 2011 Jan; 11(1):99-108. PubMed ID: 21291404
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Caveolin-1 expression in ovarian carcinoma is MDR1 independent.
    Davidson B; Goldberg I; Givant-Horwitz V; Nesland JM; Berner A; Bryne M; Risberg B; Kopolovic J; Kristensen GB; Tropé CG; van de Putte G; Reich R
    Am J Clin Pathol; 2002 Feb; 117(2):225-34. PubMed ID: 11863219
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thioredoxin-related protein 32 (TRP32) specifically reduces oxidized phosphatase of regenerating liver (PRL).
    Ishii T; Funato Y; Miki H
    J Biol Chem; 2013 Mar; 288(10):7263-70. PubMed ID: 23362275
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TSAP6 is a novel candidate marker of poor survival in metastatic high-grade serous carcinoma.
    Broner EC; Tropé CG; Reich R; Davidson B
    Hum Pathol; 2017 Feb; 60():180-187. PubMed ID: 27825812
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Over-expression of phosphatase of regenerating liver-3 correlates with tumor progression and poor prognosis in nasopharyngeal carcinoma.
    Zhou J; Wang S; Lu J; Li J; Ding Y
    Int J Cancer; 2009 Apr; 124(8):1879-86. PubMed ID: 19101992
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of the chromatin remodeling factor Rsf-1 is upregulated in ovarian carcinoma effusions and predicts poor survival.
    Davidson B; Trope' CG; Wang TL; Shih IeM
    Gynecol Oncol; 2006 Dec; 103(3):814-9. PubMed ID: 16844205
    [TBL] [Abstract][Full Text] [Related]  

  • 18. AZGP1 and SPDEF mRNA expression differentiates breast carcinoma from ovarian serous carcinoma.
    Stavnes HT; Nymoen DA; Langerød A; Holth A; Børresen Dale AL; Davidson B
    Virchows Arch; 2013 Feb; 462(2):163-73. PubMed ID: 23242172
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Snail, Slug, and Smad-interacting protein 1 as novel parameters of disease aggressiveness in metastatic ovarian and breast carcinoma.
    Elloul S; Elstrand MB; Nesland JM; Tropé CG; Kvalheim G; Goldberg I; Reich R; Davidson B
    Cancer; 2005 Apr; 103(8):1631-43. PubMed ID: 15742334
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SCARA3 mRNA is overexpressed in ovarian carcinoma compared with breast carcinoma effusions.
    Bock AJ; Nymoen DA; Brenne K; Kærn J; Davidson B
    Hum Pathol; 2012 May; 43(5):669-74. PubMed ID: 21855113
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.